Overview

Arcapta is a prescription drug approved by the Food and Drug Administration (FDA) in 2011 for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). Arcapta is not indicated for asthma or acute bronchospasms. Arcapta is also known by its drug name, Indacaterol maleate.

Arcapta is a bronchodilator, a drug that dilates the bronchi and bronchioles in the lungs, making it easier to breathe. Arcapta is believed to work by relaxing smooth muscles in the airways. Arcapta is considered a long-acting bronchodilator.

How do I take it?
Arcapta is inhaled orally once a day. Arcapta should be taken at the same time each day. The ... read more

Arcapta Neohaler (Indacaterol maleate) Questions

MyCOPDTeam is a free social network that makes it easy to find others like you and gain insights from others living with COPD.
Sign up Log in